WE CLAIM:

1. Use of a pure 5-HT_6 receptor antagonist compound, 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of dementia due to menopause, vascular dementia, chemotherapy-induced cognitive impairment, or behavioral changes in dementia, wherein the behavioral changes in dementia are selected from agitation, aggression, depression, anxiety, psychosis, disinhibition or sleep disturbances.

2. The use as claimed in claim 1, wherein the pharmaceutically acceptable salt of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole is selected from mesylate salt, hydrochloride salt, oxalate salt, succinate or tartrate salt.

3. The use as claimed in claim 1 and claim 2, wherein the pharmaceutically acceptable salt of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole is 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate.

4. The use as claimed in claim 1, wherein the medicament is for the treatment of dementia due to menopause.

5. The use as claimed in claim 1, wherein the medicament is for the treatment of vascular dementia.

6. The use as claimed in claim 1, wherein the medicament is for the treatment of chemotherapy-induced cognitive impairments.

7. The use of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate in the manufacture of a medicament for the treatment of behavioral changes in dementia selected from agitation, aggression, depression, anxiety, psychosis, disinhibition or sleep disturbances.

8. The use as claimed in claim 1 or 7, wherein the behavioral changes in dementia are selected from aggression in dementia, agitation in dementia or anxiety in dementia.

9. The use as claimed in claim 1, 7 or 8, wherein the behavioral changes in dementia are selected from aggression in Alzheimer's disease, agitation in Alzheimer's disease, anxiety in Alzheimer's disease, aggression in Parkinson's disease, agitation in Parkinson's disease or anxiety in Parkinson's disease.

10. Use of a pharmaceutical composition comprising the pure 5-HT_6 receptor antagonist as claimed in any one of the claims 1 to 3 and pharmaceutically acceptable excipients, in the manufacture of medicament for the treatment of dementia due to menopause, vascular dementia, chemotherapy-induced cognitive impairment or behavioral changes in dementia, wherein the behavioral changes in dementia are selected from agitation, aggression, depression, anxiety, psychosis, disinhibition or sleep disturbances.

11. The use as claimed in claim 10, wherein the medicament is to be administered to the patient by oral, nasal, local, dermal or parenteral routes.

12. The use as claimed in claim 10 or claim 11 wherein the medicament is to be administered to the patient one to three times per day, one to three times per week or one to three times per month.